Immunovant, Inc. (NASDAQ:IMVT) CTO Jay S. Stout Sells 2,740 Shares

Immunovant, Inc. (NASDAQ:IMVT) CTO Jay S. Stout sold 2,740 shares of Immunovant stock in a transaction on Wednesday, October 23rd. The shares were sold at an average price of $29.53, for a total value of $80,912.20. Following the completion of the sale, the chief technology officer now directly owns 142,186 shares of the company’s stock, valued at $4,198,752.58. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Immunovant Stock Down 0.9 %

IMVT opened at $30.22 on Friday. The stock has a market cap of $4.42 billion, a P/E ratio of -15.66 and a beta of 0.66. Immunovant, Inc. has a 12 month low of $24.67 and a 12 month high of $45.58. The company has a fifty day simple moving average of $30.07 and a 200 day simple moving average of $28.93.

Immunovant (NASDAQ:IMVT) last posted its earnings results on Tuesday, August 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.07). During the same quarter in the previous year, the business earned ($0.57) earnings per share. On average, equities research analysts expect that Immunovant, Inc. will post -2.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. UBS Group lowered their price objective on Immunovant from $42.00 to $41.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. Oppenheimer boosted their price target on shares of Immunovant from $47.00 to $53.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 9th. Raymond James restated an “outperform” rating and issued a $36.00 price objective on shares of Immunovant in a report on Thursday, October 10th. JPMorgan Chase & Co. lowered their target price on shares of Immunovant from $51.00 to $46.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $51.00 price target on shares of Immunovant in a research note on Monday, September 30th. Eleven analysts have rated the stock with a buy rating, According to MarketBeat, Immunovant has an average rating of “Buy” and a consensus price target of $48.10.

Hedge Funds Weigh In On Immunovant

Several institutional investors and hedge funds have recently modified their holdings of the business. Armistice Capital LLC lifted its stake in Immunovant by 57.0% in the second quarter. Armistice Capital LLC now owns 3,396,909 shares of the company’s stock valued at $89,678,000 after buying an additional 1,232,909 shares in the last quarter. Vanguard Group Inc. lifted its position in Immunovant by 11.2% in the 1st quarter. Vanguard Group Inc. now owns 6,478,304 shares of the company’s stock valued at $209,314,000 after acquiring an additional 650,506 shares in the last quarter. Alpine Global Management LLC boosted its stake in Immunovant by 34.6% in the 1st quarter. Alpine Global Management LLC now owns 1,882,704 shares of the company’s stock worth $60,830,000 after purchasing an additional 484,332 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Immunovant by 16.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,862,043 shares of the company’s stock worth $60,163,000 after purchasing an additional 259,481 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Immunovant by 198.0% in the second quarter. Assenagon Asset Management S.A. now owns 311,525 shares of the company’s stock valued at $8,224,000 after purchasing an additional 207,003 shares in the last quarter. 47.08% of the stock is currently owned by institutional investors and hedge funds.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.